Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756922 | Oral cavity | EOLP | cell aging | 33/2218 | 132/18723 | 2.10e-05 | 3.28e-04 | 33 |
GO:000854424 | Oral cavity | EOLP | epidermis development | 64/2218 | 324/18723 | 2.48e-05 | 3.68e-04 | 64 |
GO:007233226 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway by p53 class mediator | 22/2218 | 76/18723 | 4.62e-05 | 6.14e-04 | 22 |
GO:003051824 | Oral cavity | EOLP | intracellular steroid hormone receptor signaling pathway | 29/2218 | 116/18723 | 6.49e-05 | 8.10e-04 | 29 |
GO:004340123 | Oral cavity | EOLP | steroid hormone mediated signaling pathway | 32/2218 | 136/18723 | 9.85e-05 | 1.14e-03 | 32 |
GO:003021621 | Oral cavity | EOLP | keratinocyte differentiation | 32/2218 | 139/18723 | 1.52e-04 | 1.62e-03 | 32 |
GO:000863023 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway in response to DNA damage | 25/2218 | 99/18723 | 1.70e-04 | 1.78e-03 | 25 |
GO:004873224 | Oral cavity | EOLP | gland development | 77/2218 | 436/18723 | 2.05e-04 | 2.06e-03 | 77 |
GO:005067317 | Oral cavity | EOLP | epithelial cell proliferation | 75/2218 | 437/18723 | 5.90e-04 | 4.97e-03 | 75 |
GO:0002064110 | Oral cavity | EOLP | epithelial cell development | 43/2218 | 220/18723 | 6.25e-04 | 5.23e-03 | 43 |
GO:000150322 | Oral cavity | EOLP | ossification | 70/2218 | 408/18723 | 8.89e-04 | 6.81e-03 | 70 |
GO:000991323 | Oral cavity | EOLP | epidermal cell differentiation | 39/2218 | 202/18723 | 1.38e-03 | 9.56e-03 | 39 |
GO:004358822 | Oral cavity | EOLP | skin development | 48/2218 | 263/18723 | 1.49e-03 | 1.01e-02 | 48 |
GO:005140224 | Oral cavity | EOLP | neuron apoptotic process | 45/2218 | 246/18723 | 1.96e-03 | 1.25e-02 | 45 |
GO:00063383 | Oral cavity | EOLP | chromatin remodeling | 46/2218 | 255/18723 | 2.34e-03 | 1.44e-02 | 46 |
GO:00443462 | Oral cavity | EOLP | fibroblast apoptotic process | 8/2218 | 22/18723 | 2.64e-03 | 1.59e-02 | 8 |
GO:000975510 | Oral cavity | EOLP | hormone-mediated signaling pathway | 36/2218 | 190/18723 | 2.87e-03 | 1.70e-02 | 36 |
GO:004277123 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 12/2218 | 43/18723 | 3.36e-03 | 1.94e-02 | 12 |
GO:0050878110 | Oral cavity | EOLP | regulation of body fluid levels | 63/2218 | 379/18723 | 3.36e-03 | 1.94e-02 | 63 |
GO:00331448 | Oral cavity | EOLP | negative regulation of intracellular steroid hormone receptor signaling pathway | 11/2218 | 38/18723 | 3.60e-03 | 2.03e-02 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TP63 | SNV | Missense_Mutation | rs866938979 | c.566N>T | p.Ser189Leu | p.S189L | Q9H3D4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TP63 | SNV | Missense_Mutation | | c.1889N>G | p.Ser630Cys | p.S630C | Q9H3D4 | protein_coding | deleterious(0.01) | probably_damaging(0.91) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
TP63 | SNV | Missense_Mutation | novel | c.194C>A | p.Pro65His | p.P65H | Q9H3D4 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TP63 | SNV | Missense_Mutation | | c.1046N>C | p.Gly349Ala | p.G349A | Q9H3D4 | protein_coding | deleterious(0.04) | probably_damaging(0.985) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
TP63 | SNV | Missense_Mutation | novel | c.578N>T | p.Thr193Met | p.T193M | Q9H3D4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
TP63 | SNV | Missense_Mutation | | c.563N>T | p.Lys188Met | p.K188M | Q9H3D4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TP63 | SNV | Missense_Mutation | | c.563N>T | p.Lys188Met | p.K188M | Q9H3D4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
TP63 | SNV | Missense_Mutation | | c.1107N>C | p.Lys369Asn | p.K369N | Q9H3D4 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TP63 | SNV | Missense_Mutation | | c.656N>T | p.Pro219Leu | p.P219L | Q9H3D4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
TP63 | SNV | Missense_Mutation | novel | c.1694N>G | p.Phe565Cys | p.F565C | Q9H3D4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-ZJ-AAXN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |